604O Phase I dose escalation and initial dose expansion results of AMG 193: A MTA-cooperative PRMT5 inhibitor, in patients (pts) with MTAP-deleted solid tumors
2024 · Annals of Oncology · 9 citations
https://doi.org/10.1016/j.annonc.2024.08.671
J
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
16
Papers
47
Citations
5
h-index
1
i10-index
J. Rodon is an academic researcher from The University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & HER2/EGFR in Cancer Research & Monoclonal and Polyclonal Antibodies Research. The author has an h-index of 5, co-authored 14 publications.
Papers by this author
works629P Phase I study of pamiparib and cabozantinib in patients with metastatic solid tumors harboring homologous recombination deficiency (HRD)
2024 · Annals of Oncology · 0 citations
https://doi.org/10.1016/j.annonc.2024.08.696
337 (PB325): Poly(ADP-Ribose) Polymerase (PARP) inhibition in metastatic breast cancer: comparison of therapeutic outcomes between patients with BRCA1/2 mutations and other alterations
2024 · European Journal of Cancer · 0 citations
https://doi.org/10.1016/j.ejca.2024.114850
988P MD Anderson IMPACT2 study: Mutation enrichment analysis by tumor type and gene co-occurrence patterns in patients with DDR and non-DDR alterations
2025 · Annals of Oncology · 0 citations
https://doi.org/10.1016/j.annonc.2025.08.1557
Abstract PS4-06-14: Tinengotinib in advanced or metastatic HR+/HER2- and TNBC: efficacy and biomarker correlative analysis from a phase Ib/II study
2026 · Clinical Cancer Research · 0 citations
https://doi.org/10.1158/1557-3265.sabcs25-ps4-06-14
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat